The estimated Net Worth of Ran Nussbaum is at least $20.8 Million dollars as of 21 October 2022. Mr. Nussbaum owns over 47,999 units of UroGen Pharma Ltd stock worth over $20,465,412 and over the last 8 years he sold URGN stock worth over $0. In addition, he makes $317,779 as Independent Director at UroGen Pharma Ltd.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Nussbaum URGN stock SEC Form 4 insiders trading
Ran has made over 16 trades of the UroGen Pharma Ltd stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 47,999 units of URGN stock worth $285,114 on 21 October 2022.
The largest trade he's ever made was buying 5,925,925 units of UroGen Pharma Ltd stock on 13 May 2021 worth over $7,999,999. On average, Ran trades about 223,610 units every 49 days since 2017. As of 21 October 2022 he still owns at least 1,481,927 units of UroGen Pharma Ltd stock.
You can see the complete history of Mr. Nussbaum stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ran Nussbaum biography
Ran Nussbaum is Independent Director of the Company. Mr. Nussbaum is a managing partner and the co-founder of The Pontifax Group, a group of Israeli-based life sciences venture funds focusing on investments in development stage bio-pharmaceutical and med-tech technologies and a shareholder of our company. The Pontifax Group holds investments in more than 65 portfolio companies globally. He also serves as a board member on many of Pontifax’s portfolio companies, including BioBlast Pharma Ltd., Eloxx Pharmaceuticals Ltd., ArQule, Inc., Prevail Therapeutics, Inc. and Quiet Therapeutics Ltd. Mr. Nussbaum previously served as a director of Kite Pharma, Inc. (acquired by Gilead Sciences, Inc.) and cCEM Therapeutics, and as chairman of the board of directors of Ocon Medical, NasVax Ltd., Spearhead Investments (Bio) Ltd., Biomedix, Inc. and Keros Therapeutics. Mr. Nussbaum was appointed to serve on our board by Pontifax (Israel) III Limited Partnership and Pontifax Cayman III Limited, two of our shareholders, pursuant to rights granted to such shareholders under our articles of association as in effect prior to our initial public offering. Our Board believes Mr. Nussbaum’s investor experience qualifies him to serve on our board of directors.
What is the salary of Ran Nussbaum?
As the Independent Director of UroGen Pharma Ltd, the total compensation of Ran Nussbaum at UroGen Pharma Ltd is $317,779. There are 10 executives at UroGen Pharma Ltd getting paid more, with Elizabeth Barrett having the highest compensation of $25,900,800.
How old is Ran Nussbaum?
Ran Nussbaum is 47, he's been the Independent Director of UroGen Pharma Ltd since 2013. There are 15 older and no younger executives at UroGen Pharma Ltd. The oldest executive at UroGen Pharma Ltd is Stuart Holden, 77, who is the Independent Director.
What's Ran Nussbaum's mailing address?
Ran's mailing address filed with the SEC is C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421.
Insiders trading at UroGen Pharma Ltd
Over the last 7 years, insiders at UroGen Pharma Ltd have traded over $8,740,363 worth of UroGen Pharma Ltd stock and bought 33,940 units worth $791,524 . The most active insiders traders include Ran Nussbaum, Arie Belldegrun, and Kathryn E Falberg. On average, UroGen Pharma Ltd executives and independent directors trade stock every 31 days with the average trade being worth of $214,027. The most recent stock trade was executed by Mark Schoenberg on 10 June 2024, trading 10,000 units of URGN stock currently worth $138,100.
What does UroGen Pharma Ltd do?
urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.
What does UroGen Pharma Ltd's logo look like?
Complete history of Mr. Nussbaum stock trades at UroGen Pharma Ltd, Eloxx Pharmaceuticals Inc, Prevail Therapeutics Inc, and Keros Therapeutics
UroGen Pharma Ltd executives and stock owners
UroGen Pharma Ltd executives and other stock owners filed with the SEC include:
-
Elizabeth Barrett,
President, Chief Executive Officer, Director -
Elizabeth A. Barrett,
Pres, CEO & Director -
Mark Schoenberg,
Chief Medical Officer -
Ron Bentsur,
Advisor -
Dr. Mark P. Schoenberg,
Chief Medical Officer -
Arie Belldegrun,
Independent Chairman of the Board -
Jason Drew Smith,
Gen. Counsel & Chief Compliance Officer -
Cynthia Butitta,
Independent Director -
Kathryn Falberg,
Independent Director -
Stuart Holden,
Independent Director -
Ran Nussbaum,
Independent Director -
Fred Cohen,
Independent Director -
Shawn Tomasello,
Independent Director -
Molly Henderson CPA, MBA,
Chief Financial Officer -
Elyse Seltzer,
Chief Development Officer -
Polly Murphy,
Chief Business Officer -
Jeff Bova,
Chief Commercial Officer -
Jason Smith,
Chief Compliance Officer, General Counsel -
Jim Ottinger,
Executive Vice President, Regulatory Affairs and Quality -
Marina Konorty,
Executive Vice President, Research & Development and Technical Operations -
Molly Henderson,
Chief Financial Officer, Principal Accounting Officer -
James Ottinger R.ph.,
Exec. VP of Regulatory Affairs & Quality -
Jeffrey Bova M.B.A.,
Chief Commercial Officer -
Dr. Sari Prutchi-Sagiv Ph.D.,
Marketing Director -
Eric Van Zanten,
Sr. Director of Communications -
Jason Smith,
Gen. Counsel & Chief Compliance Officer -
Sara Blum Sherman,
Sr. Director of Investor Relations -
James A. Jr. Robinson,
Director -
Investments Iv, L.P.Pro Que...,
-
Stephen Mullennix,
Chief Operating Officer -
Peter P. Pfreundschuh,
Chief Financial Officer -
Leana Wen,
Director -
Dong Kim,
Chief Financial Officer -
Daniel George Wildman,
Director